Thursday, May 28, 2026, 1:00–2:00 PM ET
This session is designed to improve understanding and application of recent updates to synoptic pathology reporting protocols such as the latest Reporting Template for Reporting Results of Biomarker Testing of Specimens from Patients with Carcinoma of the Breast. These changes reflect evolving clinical guidelines that directly influence diagnostic accuracy and treatment selection in breast cancer care.
Webinar presenters Thaer Khoury, MD, FCAP, Chair, Pathology and Laboratory Medicine, Roswell Park Comprehensive Cancer Cente, and Colin Murphy, CEO of mTuitive.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Wednesday, June 24, 2026, 12:00–1:00 PM ET
Hear an expert discuss the expanded clinical utility of HER2 IHC scoring in metastatic breast cancer and its impact on your practice
Webinar presenters Michelle Shiller, DO, AP, CP, MGP, FACP, Baylor University Medical Center.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
May 2018—Sysmex America announced the availability of its first fully automated urine particle counter and digital imaging system, the UN-2000. The scalable system is composed of the UF-5000 automated urine particle analyzer and UD-10 automated urine particle digital imaging device.
May 2019—Sakura Finetek USA launched two ready-to-use antibodies in the United States and eight outside the U.S. for use on the Tissue-Tek Genie Advanced Staining System.
May 2019—Bio SB announced its line of Fast Mohs IHC antibodies and detection systems for immunohistochemical cancer detection on frozen tissue after Mohs surgery.
April 2019—Luminex has completed its acquisition of MilliporeSigma’s flow cytometry portfolio for $75 million. The flow cytometry portfolio includes the Amnis family of imaging flow cytometry products for cell-based analysis and the Guava portfolio of microcapillary flow cytometry systems. “The Amnis and Guava products complement our wide range of existing flow-based offerings, further differentiating our portfolio and ensuring we are well positioned to support customers today and into the future,” Homi Shamir, president and CEO of Luminex, said in a press release. “With this acquisition, we now have expanded our installed base to include more than 5,000 flow cytometry systems worldwide, adding to our impressive footprint and creating the potential for additional meaningful growth.” The buyout is expected to contribute $40–$50 million in revenue to Luminex this year.
April 2019—The Food and Drug Administration approved trastuzumab and hyaluronidase-oysk (Herceptin Hylecta, Genentech) for subcutaneous injection for the treatment of certain people with HER2-positive early breast cancer in combination with chemotherapy and HER2-positive metastatic breast cancer in combination with paclitaxel or alone in people who have received one or more chemotherapy regimens for metastatic disease.
April 2019—Audit MicroControls announced several additions to its line of calibration verification/linearity and daily quality control products. The company’s galectin-3 linearity and control kits are for use with quantitative assays on clinical laboratory analyzers, simulating human patient samples.
April 2019—Worthington Biomedical Corp. has released the 18th edition of its Tissue Dissociation Guide for biochemistry, cell biology, molecular biology, preclinical research, and bioprocessing applications.
April 2019—Hardy Diagnostics is now an authorized distributor of EliTech’s Mycofast US, a rapid system to detect, enumerate, and identify genital Mycoplasma hominis and Ureaplasma urealyticum.
April 2019—NeoGenomics announced availability of the Ventana PD-L1 (SP142) Assay for tumor tissue from patients with the triple negative subtype of breast cancer.
